查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
2030 年中樞神經系統藥物市場預測：按疾病、藥物類別、配銷通路、年齡層和地區進行的全球分析
市場調查報告書
商品編碼
1383398

2030 年中樞神經系統藥物市場預測：按疾病、藥物類別、配銷通路、年齡層和地區進行的全球分析

Central Nervous System Therapeutics Market Forecasts to 2030 - Global Analysis By Disease, Drug Classes,Distribution Channel, Age Group and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球中樞神經系統治療市場規模為 1,047 億美元，預測期內年複合成長率為 8.2%，到 2030 年將達到 1,821.2 億美元。

中樞神經系統 (CNS) 藥物是用於治療腦部和脊髓疾病的藥物。中樞神經系統治療藥物是一個廣泛的藥物類別，包括許多不同類型的藥物，每種藥物都有特異性的作用機制。中樞神經系統藥物用於治療各種神經和精神疾病。常見的中樞神經系統藥物包括用於治療憂鬱症和某些焦慮症的抗憂鬱症藥物、用於抑制癲癇發作的抗癲癇藥物（這對於治療癲癇、思覺失調症和躁鬱症至關重要），以及用於治療精神障礙的抗精神病藥物。

世界衛生組織 (WHO) 報告稱，全球有超過 5500 萬人受到失智症影響，每年報告近 1000 萬新病例。

創新藥物輸送系統的開發

治療中樞神經系統疾病的新治療方法的發展導致了創新藥物傳遞系統的出現。這些尖端給藥系統的誕生有望加速中樞神經系統市場的擴張。現代治療方法和藥物傳輸技術副作用極小或沒有。此外，大眾對神經退化性疾病和心理健康知識的了解不斷增加，預計對中樞神經系統藥物的需求將受到顯著影響。

中樞神經系統藥物高成本

CNS藥物需要大量的研究和開發，這增加了CNS藥物製造商的成本並提高了最終產品的價格。核准期限越長，投資風險越大。因此，中樞神經系統疾病藥物供應商對其產品收取高價，以收回成本並保持盈利。然而，所有這些問題都對患者獲得中樞神經系統藥物產生負面影響，過高的定價甚至會阻礙中樞神經系統藥物在消費潛力較低的地區的銷售。這些因素是市場擴張的主要障礙。

民族意識

人們對心理健康和神經疾病的意識顯著增強。這種認知的提高使得早期發現和治療成為可能，因此，對中樞神經系統治療的需求正在增加。此外，隨著政府和醫療機構越來越認知到心理健康的重要性，醫療基礎設施正在改善，醫療法規也已到位，以促進中樞神經系統藥物的生產和分配。這導致了市場成長。

抗藥性

中樞神經系統（CNS）治療市場受到抗藥性威脅的困擾。這種症候群常見於癲癇等疾病，患者逐漸對先前有效的藥物變得不耐受。這不僅降低了治療效果，還需要開發新的治療方法。抗藥性使得治療中樞神經系統疾病變得更加困難，因此研究人員必須不斷想出新的解決方案來解決這個問題。抗藥性患者可能很難找到有效的藥物，對疾病的控制能力較差，並且可能需要更強化的治療。這些因素都阻礙了市場需求。

COVID-19 的影響

中樞神經系統治療市場受到了 COVID-19大流行的嚴重影響。受疫情影響，接受中樞神經系統疾病治療的人數甚至核准治療中樞神經系統的新藥數量都減少了。此外，大流行擾亂了正在進行的中樞神經系統疾病的治療研究和臨床試驗。由於患者招募限制、醫療設施使用受限以及優先考慮 COVID-19 研究，一些臨床試驗不得不取消或擱置。結果，新的中樞神經系統藥物的開發和監管核准被推遲。

預計抗憂鬱症市場在預測期內將是最大的市場。

抗憂鬱症市場估計佔最大佔有率。其中包括增加對憂鬱症和焦慮等精神健康疾病的認知和識別，改善獲得精神健康服務的機會，以及抗憂鬱症在治療各種中樞神經系統疾病中的效用和有效性。這是精神健康疾病率上升的一個因素失調。抗憂鬱症的開發在製藥部門取得了重大進展。創新類型的抗憂鬱症，例如選擇性選擇性血清素再回收抑制劑（SSRI）、血清素和去甲腎上腺素再回收抑制劑（SNRI）以及非典型抗憂鬱症，與老一代藥物相比具有更高的療效和耐受性。

預計兒童產業在預測期內將經歷最高的年複合成長率。

預計兒童細分市場在預測期內將出現良好成長。神經系統治療市場的兒童部門專門為患有神經系統疾病和失調的兒童提供專門的治療解決方案和方案。這包括遺傳性疾病、癲癇、腦性麻痹麻痺、過動症、泛自閉症障礙等。此類別重點在於兒童用藥物製劑、兒童醫療設備以及適齡診斷設備的生產和銷售。開拓早期療育意識、兒童神經系統疾病的發生率、兒童神經學研究和治療方法發展都是推動市場的因素。

比最大的地區

由於製藥業的技術進步有助於開發新藥、產品上市增加、中樞神經系統疾病負擔增加以及美國。獲得。此外，神經系統疾病盛行率的上升可能會增加對提供尖端治療方法方法的研究計劃的資金和支持，從而加速市場擴張。

複合年複合成長率最高的地區：

預計亞太地區在預測期內將實現盈利成長。主要的市場促進因素是政府在加強醫療基礎設施方面的投資不斷增加，以及大量患者的醫療需求未被滿足。該非營利組織透過提高人們對心理健康和中樞神經系統藥物的認知，同時為中樞神經系統疾病提供免費治療，做出了巨大的貢獻。

提供免費客製化：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 利害關係人
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章 市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球中樞神經系統治療市場：依疾病分類

  • 神經血管疾病
  • 精神健康
    • 焦慮症
    • 癲癇
    • 情緒障礙
    • 精神障礙
  • 退化性疾病
    • 帕金森氏症
    • 阿茲海默症
    • 亨丁頓舞蹈症
    • 多發性硬化症
    • 肌萎縮側索硬化症
  • 中樞神經系統創傷
  • 中樞神經系統癌症
  • 感染疾病
  • 其他疾病

第6章 全球中樞神經系統治療市場：依藥物類別

  • 抗憂鬱症
  • 止痛藥
  • 麻醉劑
  • 抗帕金森氏症藥物
  • 抗癲癇藥
  • 脫羧酶抑制劑
  • 多巴胺促效劑
  • 免疫調節劑
  • 其他藥物類別

第7章 全球中樞神經系統治療市場：按配銷通路

  • 零售藥房
  • 醫院藥房
  • 網路藥房

第8章 全球中樞神經系統治療市場：依年齡層別

  • 兒童
  • 老年人
  • 成人

第9章 全球中樞神經系統治療市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第10章 進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第11章公司簡介

  • Biogen
  • Astra Zeneca
  • Eli Lilly and Company
  • Merck & Co.
  • Johnson & Johnson Services, Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Hand Pharma, Inc.
  • Novartis AG
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Shire PLC
  • GlaxoSmithKline PLC
  • Pfizer, Inc.
Product Code: SMRC24248

According to Stratistics MRC, the Global Central Nervous System Therapeutics Market is accounted for $104.7 billion in 2023 and is expected to reach $182.12 billion by 2030 growing at a CAGR of 8.2% during the forecast period. Central Nervous System (CNS) therapeutics are drugs that are used to treat diseases of the brain and spinal cord. They are a broad class of drugs that include many different types, each with its own specific mechanism of action. CNS therapeutics is used to treat a wide range of neurological and psychiatric conditions. Some common CNS therapeutics include antidepressants, which are used to treat depression and certain anxiety disorders, anti-epileptics, which are used to control seizures and are essential in the treatment of epilepsy, antipsychotics, which are used to manage psychotic disorders like schizophrenia and bipolar disorders, etc.

According to the World Health Organization (WHO) report, more than 55 million people have dementia worldwide, and nearly 10 million new cases are reported yearly.

Market Dynamics:

Driver:

Development of innovative drug delivery systems

Innovative drug delivery systems have emerged as a result of the development of new therapies for the treatment of illnesses of the central nervous system. The creation of these cutting-edge drug delivery systems is anticipated to accelerate the expansion of the market for the central nervous system. The adverse effects of modern treatments and medication delivery technologies are minimal or nonexistent. Additionally, the demand for therapies for the central nervous system is anticipated to be significantly impacted by the population's growing knowledge of neurodegenerative diseases and mental health.

Restraint:

High costs of CNS drugs

CNS medications require considerable research and development, which is expensive for CNS drug makers and raises the final product's cost. Longer approval durations further raise the risk of investing; thus, CNS drug suppliers price their goods high to recover their expenses and maintain profitability. However, these issues all have a negative impact on patients who acquire these CNS medications and excessive prices even prevent the sale of CNS medications in areas with little spending potential. These elements are significant barriers to market expansion.

Opportunity:

Public awareness

Public awareness about mental health and neurological disorders has grown significantly. The need for CNS medications has increased as a result of the early identification and treatment made possible by this enhanced awareness. Additionally, governments and healthcare institutions are becoming more aware of the significance of mental health, which has improved healthcare infrastructure and led to better healthcare regulations that promote the creation and distribution of CNS medications. Therefore, it leads to market growth.

Threat:

Drug resistance

The therapeutic market for the central nervous system (CNS) is concerned by the threat of drug resistance. Patients gradually become less receptive to previously effective drugs in this syndrome, which is frequently seen in disorders like epilepsy. It not only lowers therapy effectiveness but also forces the creation of new treatments. Drug resistance makes treating CNS illnesses more difficult, and researchers must constantly come up with new solutions to this problem. Patients who have resistance can have trouble locating effective medications, which could lead to insufficient illness control and the requirement for more intrusive measures. These factors hinder market demand.

COVID-19 Impact

The market for treatments for the central nervous system was significantly impacted by the COVID-19 pandemic. Even the number of people receiving treatment for CNS illnesses and the number of new CNS drugs approved has decreased as a result of the epidemic. Additionally, the pandemic interfered with ongoing CNS therapeutic research and clinical trials. Due to limitations on patient recruitment, restricted access to medical facilities, and the priority given to COVID-19 research, several trials had to be stopped or put on hold. New CNS medicines' development and regulatory approval were subsequently delayed as a result.

The antidepressant segment is expected to be the largest during the forecast period.

The antidepressant segment is estimated to hold the largest share. Increased knowledge and identification of mental health conditions like depression and anxiety, better access to mental health services, and the usefulness and efficacy of antidepressants in treating a variety of CNS illnesses are all contributing factors to the rising prevalence of mental health problems like these. Antidepressant medication development has advanced significantly in the pharmaceutical sector. Innovative types of antidepressants, such as selective serotonin reuptake inhibitors (SSRIs), serotonin-nor epinephrine reuptake inhibitors (SNRIs), and atypical antidepressants, offer higher efficacy and tolerability profiles as compared to earlier generations of medications.

The paediatric segment is expected to have the highest CAGR during the forecast period.

The paediatric segment is anticipated to have lucrative growth during the forecast period. The Paediatric segment of the Nervous System Therapeutics Market is dedicated to therapeutic solutions and regimens created especially for children with neurological illnesses and disorders. These include hereditary illnesses, epilepsy, cerebral palsy, ADHD, and autism spectrum disorders. The category focuses on the creation and distribution of paediatric medication formulations, kid-friendly medical gadgets, and age-appropriate diagnostic equipment. Growing awareness of early intervention, the frequency of neurological illnesses in children, and developments in paediatric neurology research and therapies are all driving factors in the market.

Region with largest share:

North America commanded the largest market share during the extrapolated period owing to the growth of technology in the pharmaceutical sector that helps in new drug developments, increasing product launches, the rising burden of central nervous system diseases, and the rising level of research and developments in the countries like the United States and Canada. Additionally, the prevalence of neurological disorders is rising, which increases funding and support for research initiatives that provide cutting-edge therapies and could accelerate the market's expansion.

Region with highest CAGR:

Asia Pacific is expected to witness profitable growth over the projection period. The major market drivers are the growing government investments in enhancing the healthcare infrastructure and the prevalence of numerous patients with unmet medical needs. The non-profit organisations are doing an outstanding job of raising awareness about mental health and CNS therapeutics while also offering free treatments for CNS illnesses.

Key players in the market

Some of the key players in the Central Nervous System Therapeutics Market include: Biogen, Astra Zeneca, Eli Lilly and Company, Merck & Co., Johnson & Johnson Services, Inc., Otsuka Pharmaceutical Co., Ltd., Hand Pharma, Inc., Novartis AG, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Shire PLC, GlaxoSmithKline PLC and Pfizer, Inc.

Key Developments:

In February 2023, Sage Therapeutics, Inc. and Biogen Inc received acceptance from the United States FDA for a New Drug Application (NDA) application for zuranolone in the treatment of the major depressive disorder (MDD) and postpartum depression (PPD).

In January 2023, Biogen Inc. received Accelerated Approval from United States FDA for lecanemab-irmb (LEQEMBI) 100 mg/mL injection for intravenous use, a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta (AB) for the treatment of Alzheimer's disease (AD).

Diseases Covered:

  • Neurovascular Diseases
  • Mental Health
  • Degenerative Disorders
  • CNS Trauma
  • CNS Cancer
  • Infectious Diseases
  • Other Diseases

Drug Classes Covered:

  • Antidepressant
  • Analgesics
  • Anesthetics
  • Anti-Parkinson Drugs
  • Anti-Epileptics
  • Decarboxylase Inhibitors
  • Dopamine Agonists
  • Immunomodulatory Drug
  • Other Drug Classes

Distribution Channels Covered:

  • Retail Pharmacy
  • Hospital-Based Pharmacies
  • Online Pharmacy

Age Groups Covered:

  • Pediatric
  • Geriatric
  • Adults

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Emerging Markets
  • 3.7 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Central Nervous System Therapeutics Market, By Disease

  • 5.1 Introduction
  • 5.2 Neurovascular Diseases
  • 5.3 Mental Health
    • 5.3.1 Anxiety Disorders
    • 5.3.2 Epilepsy
    • 5.3.3 Mood Disorders
    • 5.3.4 Psychotic Disorders
  • 5.4 Degenerative Disorders
    • 5.4.1 Parkinson's Disease
    • 5.4.2 Alzheimer's Disease
    • 5.4.3 Huntington's Disease
    • 5.4.4 Multiple Sclerosis
    • 5.4.5 Amyotrophic Lateral Sclerosis
  • 5.5 CNS Trauma
  • 5.6 CNS Cancer
  • 5.7 Infectious Diseases
  • 5.8 Other Diseases

6 Global Central Nervous System Therapeutics Market, By Drug Class

  • 6.1 Introduction
  • 6.2 Antidepressant
  • 6.3 Analgesics
  • 6.4 Anesthetics
  • 6.5 Anti-Parkinson Drugs
  • 6.6 Anti-Epileptics
  • 6.7 Decarboxylase Inhibitors
  • 6.8 Dopamine Agonists
  • 6.9 Immunomodulatory Drug
  • 6.10 Other Drug Classes

7 Global Central Nervous System Therapeutics Market, By Distribution Channel

  • 7.1 Introduction
  • 7.2 Retail Pharmacy
  • 7.3 Hospital-Based Pharmacies
  • 7.4 Online Pharmacy

8 Global Central Nervous System Therapeutics Market, By Age Group

  • 8.1 Introduction
  • 8.2 Pediatric
  • 8.3 Geriatric
  • 8.4 Adults

9 Global Central Nervous System Therapeutics Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Biogen
  • 11.2 Astra Zeneca
  • 11.3 Eli Lilly and Company
  • 11.4 Merck & Co.
  • 11.5 Johnson & Johnson Services, Inc.
  • 11.6 Otsuka Pharmaceutical Co., Ltd.
  • 11.7 Hand Pharma, Inc.
  • 11.8 Novartis AG
  • 11.9 Takeda Pharmaceutical Company Limited
  • 11.10 Teva Pharmaceutical Industries Ltd.
  • 11.11 Shire PLC
  • 11.12 GlaxoSmithKline PLC
  • 11.13 Pfizer, Inc.

List of Tables

  • Table 1 Global Central Nervous System Therapeutics Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Central Nervous System Therapeutics Market Outlook, By Disease (2021-2030) ($MN)
  • Table 3 Global Central Nervous System Therapeutics Market Outlook, By Neurovascular Diseases (2021-2030) ($MN)
  • Table 4 Global Central Nervous System Therapeutics Market Outlook, By Mental Health (2021-2030) ($MN)
  • Table 5 Global Central Nervous System Therapeutics Market Outlook, By Anxiety Disorders (2021-2030) ($MN)
  • Table 6 Global Central Nervous System Therapeutics Market Outlook, By Epilepsy (2021-2030) ($MN)
  • Table 7 Global Central Nervous System Therapeutics Market Outlook, By Mood Disorders (2021-2030) ($MN)
  • Table 8 Global Central Nervous System Therapeutics Market Outlook, By Psychotic Disorders (2021-2030) ($MN)
  • Table 9 Global Central Nervous System Therapeutics Market Outlook, By Degenerative Disorders (2021-2030) ($MN)
  • Table 10 Global Central Nervous System Therapeutics Market Outlook, By Parkinson's Disease (2021-2030) ($MN)
  • Table 11 Global Central Nervous System Therapeutics Market Outlook, By Alzheimer's Disease (2021-2030) ($MN)
  • Table 12 Global Central Nervous System Therapeutics Market Outlook, By Huntington's Disease (2021-2030) ($MN)
  • Table 13 Global Central Nervous System Therapeutics Market Outlook, By Multiple Sclerosis (2021-2030) ($MN)
  • Table 14 Global Central Nervous System Therapeutics Market Outlook, By Amyotrophic Lateral Sclerosis (2021-2030) ($MN)
  • Table 15 Global Central Nervous System Therapeutics Market Outlook, By CNS Trauma (2021-2030) ($MN)
  • Table 16 Global Central Nervous System Therapeutics Market Outlook, By CNS Cancer (2021-2030) ($MN)
  • Table 17 Global Central Nervous System Therapeutics Market Outlook, By Infectious Diseases (2021-2030) ($MN)
  • Table 18 Global Central Nervous System Therapeutics Market Outlook, By Other Diseases (2021-2030) ($MN)
  • Table 19 Global Central Nervous System Therapeutics Market Outlook, By Drug Class (2021-2030) ($MN)
  • Table 20 Global Central Nervous System Therapeutics Market Outlook, By Antidepressant (2021-2030) ($MN)
  • Table 21 Global Central Nervous System Therapeutics Market Outlook, By Analgesics (2021-2030) ($MN)
  • Table 22 Global Central Nervous System Therapeutics Market Outlook, By Anesthetics (2021-2030) ($MN)
  • Table 23 Global Central Nervous System Therapeutics Market Outlook, By Anti-Parkinson Drugs (2021-2030) ($MN)
  • Table 24 Global Central Nervous System Therapeutics Market Outlook, By Anti-Epileptics (2021-2030) ($MN)
  • Table 25 Global Central Nervous System Therapeutics Market Outlook, By Decarboxylase Inhibitors (2021-2030) ($MN)
  • Table 26 Global Central Nervous System Therapeutics Market Outlook, By Dopamine Agonists (2021-2030) ($MN)
  • Table 27 Global Central Nervous System Therapeutics Market Outlook, By Immunomodulatory Drug (2021-2030) ($MN)
  • Table 28 Global Central Nervous System Therapeutics Market Outlook, By Other Drug Classes (2021-2030) ($MN)
  • Table 29 Global Central Nervous System Therapeutics Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 30 Global Central Nervous System Therapeutics Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 31 Global Central Nervous System Therapeutics Market Outlook, By Hospital-Based Pharmacies (2021-2030) ($MN)
  • Table 32 Global Central Nervous System Therapeutics Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 33 Global Central Nervous System Therapeutics Market Outlook, By Age Group (2021-2030) ($MN)
  • Table 34 Global Central Nervous System Therapeutics Market Outlook, By Pediatric (2021-2030) ($MN)
  • Table 35 Global Central Nervous System Therapeutics Market Outlook, By Geriatric (2021-2030) ($MN)
  • Table 36 Global Central Nervous System Therapeutics Market Outlook, By Adults (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.